ZVRA

ANALYST NOTE: ZEVRA THERAPEUTICS, INC. (ZVRA) Date: 2026-06-13 Analyst: StoryStocks-Native Equity Research

1. Structural Readiness

• Conservative Entry: $13.66
• Current Price: $12.90
• Breakout Level: $13.66 (Conservative).
• ATR Context: The ATR at the time of the original breakout signal was 5.3% (High), and the current ATR is 5.5% (High). This indicates elevated volatility, which is consistent with the "High" bucket (4–6%) historically associated with structural quality in this sector, though it requires careful position sizing.
• Pivot Strength: Swing.
• Cap Bucket: Small.

2. Thesis Layer

• Primary Secular Theme: Biotech & GLP-1 → Rare & Orphan (Tier Direct).
• Thesis Weighting: High Confidence.
• Exposure Analysis: ZVRA is a direct beneficiary of the "Rare & Orphan" secular wave. The company's primary growth engine, MIPLYFFA, addresses Niemann-Pick disease type C (NPC), a condition with a high unmet need and a defined, albeit small, patient population. The setup is not merely speculative; it is anchored in a product that has already achieved FDA approval and is generating revenue. The "Rare & Orphan" classification is reinforced by the company's strategic focus on high-unmet-need CNS conditions, including VEDS and Idiopathic Hypersomnia, which aligns with the broader market preference for differentiated therapies in niche populations where pricing power and reimbursement stability are often superior to mass-market competitors.

3. Business Overview

Zevra Therapeutics operates as a commercial-stage biopharmaceutical company focused on rare diseases and CNS disorders. Its business model relies on the commercialization of approved therapies and the advancement of a pipeline of investigational products.

• Commercial Portfolio (Revenue Drivers):
• MIPLYFFA: Approved by the FDA on September 20, 2024, for the treatment of neurological manifestations of NPC in combination with miglustat. As of March 31, 2026, the company reported $36.2 million in total net revenue for the first quarter, representing a 78% increase year-over-year compared to Q1 2025.
• Enrollment & Adoption: As of March 31, 2026, there were 170 prescription enrollment forms for MIPLYFFA. The company noted that 9 of these were received in the first quarter of 2026. The company estimates the U.S. diagnosed population to be between 300 and 350 patients, suggesting the current enrollment represents a significant portion of the addressable market.
• OLPRUVA: Approved as adjunctive therapy for Urea Cycle Disorders (UCDs). Revenue from OLPRUVA was $0.3 million for the three months ended March 31, 2026, and $0.8 million for the full year 2025.
• Pipeline & Clinical Progress:
• DiSCOVER Trial (Celiprolol): An event-driven Phase 3 study for Vascular Ehlers-Danlos Syndrome (VEDS). As of the Q1 2026 earnings call, 62 patients were enrolled, with 2 confirmed events out of the 28 required to trigger an interim analysis.
• Expanded Access Program (EAP): As of March 31, 2026, 122 patients were enrolled in the EAP across various geographies.
• Financial Position:
• As of March 31, 2026, total cash, cash equivalents, and investments stood at $236.8 million, a decrease of $2.1 million from the prior quarter. This liquidity position, bolstered by the $148.3 million net proceeds from the PRV sale in April 2025, provides a runway to support commercial expansion and clinical trials.

4. Archetype and Conviction

• Archetype: Growth Leader.
• *Rationale:* The company fits the "Growth Leader" archetype due to the rapid revenue acceleration (78% YoY growth in Q1 2026) driven by the commercial ramp of a newly approved, first-in-class therapy (MIPLYFFA). The business is transitioning from a pure R&D entity to a commercial operator with a clear path to profitability as enrollment scales.
• Valuation & Financial Spine:
• The financial spine indicates a forward consensus EPS of 1.1 for FY1 and 1.033 for FY2. This suggests the market is pricing in a transition to earnings positivity, which supports the "Growth Leader" classification over a "Deep Value" or "Turnaround" narrative.
• Conviction Stack:
• Thesis Strength: High. The "Rare & Orphan" theme is a structural tailwind, and ZVRA is a direct, tier-1 beneficiary.
• Evidence Quality: Strong. The evidence base (E1–E26) is robust, citing specific revenue figures, enrollment numbers, and cash positions from Q1 2026 earnings and SEC filings.
• Rerating Potential: Significant. As the company moves from "launch phase" to "commercial scaling," the market may re-rate the stock from a binary clinical-risk asset to a revenue-growth asset.

5. Invalidations, Strengtheners, and Gaps

• Invalidation Triggers:
• Significant delays in the DiSCOVER trial enrollment or a failure to meet the 28-event threshold for the interim analysis could dampen the growth narrative.
• Strengtheners:
• Confirmation of the interim analysis results from the DiSCOVER trial.
• Acceleration in MIPLYFFA enrollment rates beyond the current 9 prescriptions per quarter pace.
• Successful EMA approval for MIPLYFFA (MAA filed July 2025, currently under review).
• Evidence Gaps:
• European Commercialization Timeline: While the MAA is under review, specific details on the expected launch date and pricing strategy in Europe (where the market is estimated at 1,100 patients) are not yet quantified in the provided evidence.
• Long-term Reimbursement: While revenue is growing, specific details on net pricing and reimbursement rates for MIPLYFFA in the U.S. vs. Europe are not explicitly detailed in the provided snippets, which could impact margin expansion assumptions.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: High Key evidence: 78% YoY revenue growth in Q1 2026 driven by MIPLYFFA commercialization; $236.8M cash runway as of March 31, 2026; First-in-class FDA-approved therapy for NPC with 170 enrollments. Key risks: Slow commercial adoption rates relative to the 300-350 diagnosed U.S. patient population; potential delays in EMA approval for European expansion; clinical trial enrollment pace in the DiSCOVER study. Sizing hint: Position size should account for the "High" ATR volatility (5.5%) and the "Forming" state of the setup; consider scaling in on a confirmed breakout above $13.66. Expected path: Management expects continued revenue growth as MIPLYFFA enrollment expands; the company is positioned to report positive EPS in FY1 and FY2 as commercial margins improve. Expected horizon: 6 to 12 months for the setup to resolve into a confirmed breakout or for the next major catalyst (EMA decision or DiSCOVER interim data).